Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations
ATMAII
1 other identifier
observational
365
1 country
1
Brief Summary
Food allergy is a common chronic condition in childhood. Recent studies have suggested that the natural history of food allergy has changed during the last two decades, with an increased prevalence, severity of clinical manifestations, and risk of persistence into later ages. The increased food allergy prevalence in children has an important economic impact, with significant direct costs for the healthcare system and even larger costs for the families of food-allergic patients. In addition, children with food allergies are at increased risk to develop other allergic manifestations later in life. According to a recent study, children with a food allergy are 2 to 4 times more likely to develop other atopic manifestations such as asthma (4.0 times), atopic eczema (2.4 times), and respiratory allergies (3.6 times), compared to children without a food allergy. Cow's milk allergy is among the most common food allergy in early childhood, with an estimated prevalence of 2% to 3%. It has been previously showed that in children with cow milk allergy, an extensively hydrolysed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG induced higher tolerance rates compared to extensively hydrolysed casein formula without Lactobacillus rhamnosus GG and other formulas. These findings were consistent with those of a 1-year follow-up study performed in the US that showed better outcomes using an extensively hydrolysed casein formula+Lactobacillus rhamnosus GG vs. an extensively hydrolysed casein formula or amino acid-based formula for the first-line dietary management of cow milk allergy. In addition it has been recently demonstrated that extensively hydrolysed casein formula + Lactobacillus rhamnosus GG reduces the incidence of other atopic manifestations and hastens the development of oral tolerance in children with IgE-mediated cow milk allergy. The present randomized controlled trial (RCT) was designed to test whether different dietary interventions could influence the occurrence of other atopic manifestations in children with IgE-mediated cow milk allergy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
February 21, 2019
CompletedFirst Posted
Study publicly available on registry
March 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJune 26, 2024
June 1, 2024
5.4 years
February 21, 2019
June 25, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Rate of subjects with occurrence of other of allergic manifestations
To evaluate the effect of different dietary strategies on the occurrence of eczema, urticaria, asthma and rhinoconjunctivitis in children with IgE-mediated cow milk allergy
3 years
Secondary Outcomes (7)
Rate of subjects with tolerance acquisition to cow's milk
3 years
Change in metagenomics and metabolomics
3 years
Epigenetic modifications in cytokines genes
3 years
Epigenetic modifications in cytokines genes
3 years
Rate of subjects with occurrence of other of allergic manifestations
after 4 to 6 years follow-up
- +2 more secondary outcomes
Study Arms (5)
extensively hydrolyzed casein formula+LGG
subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
extensively hydrolyzed whey formula;
subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
hydrolyzed rice formula
subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
soy based formula
subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
amino-acid based formula
subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
Interventions
hypoallergenic formulas used for cow milk allergy treatment
Eligibility Criteria
Children who were consecutively observed at a FP office because the recent occurrence of signs and symptoms possibly related to IgE-mediated CMA were sent to our tertiary centre for paediatric allergy for possible inclusion in the study. Only subjects who met the inclusion criteria will be invited to participate to the study.Written informed consent will be obtained from the parents of each subject. Anamnestic, demographic, anthropometric and clinical data, as well as information on socio-demographic factors, family and living conditions, parental history of allergic diseases, maternal smoking during pregnancy, environmental tobacco smoke exposure, number of siblings, and pet ownership were obtained from the parents and recorded in a clinical database. For children with sure diagnosis of IgE-mediated CMA during a 3-year follow-up,3 visits every 12 months will be performed. Stool samples for metagenomics and metabolomics and blood sample for epigenetics studies will be collected.
You may qualify if:
- age 1-12 months
- IgE-mediated CMA
You may not qualify if:
- cow's milk protein-induced anaphylaxis,
- food protein induced enterocolitis syndrome,
- other food allergies,
- other allergic diseases,
- non-CMA-related atopic eczema,
- eosinophilic disorders of the gastrointestinal tract,
- chronic systemic diseases,
- congenital cardiac defects,
- active tuberculosis,
- autoimmune diseases,
- immunodeficiency,
- chronic inflammatory bowel diseases,
- celiac disease,
- cystic fibrosis,
- metabolic diseases,
- +4 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Naples Federico II
Naples, 80131, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
February 21, 2019
First Posted
March 4, 2019
Study Start
December 1, 2014
Primary Completion
May 1, 2020
Study Completion
December 1, 2021
Last Updated
June 26, 2024
Record last verified: 2024-06